1423 / 1542
ASCENDE- RT trial
BUT higher late G3+
GU (
18% in BT boost
arm vs. 8% in EBRT
alone
)
Most strictures and
urinary incontinence
Recommended boost
dose reduced to
110Gy
Morris WJ, et al. ASCENDE-RT: A multicenter, randomized trial of dose-escalated external beam
radiiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-
riisk localized prostate cancer. JCO 2015;33 (suppl 7) abstr 3.